IMMULITE 2000 XPI ANTI-HBS

Test, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)

FDA Premarket Approval P010052

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the immulite anti-hbs and immulite 2000 anti-hbs. The devices are indicated for: immulite anti-hbs: for in vitro diagnostic use with the immulite automated immunoassay analyzer for the qualitative measurement of total antibodies to the hepatitis b surface antigen (anti-hbs) in human serum and plasma (heparinized or edta). Assay results may be used as an aid in the determination of susceptibility to hepatitis b virus (hbv) infection for individuals prior to or following hbv vaccination, or where vaccination status is unknown. Assay results may be used with other hbv serological markers for the laboratory diagnosis of hbv disease associated with hbv infection. A reactive assay result will allow a differential diagnosis in individuals displaying signs and symptoms of hepatitis in whom etiology is unknown. The detection of anti-hbs is indicative of laboratory diagnosis of seroconversion from hepatitis b virus (hbv) infection. Immulite 2000 anti-hbs: for in vitro diagnostic use with the immulite 2000 automated immunoassay analyzer for the qualitative measurement of total antibodies to the hepatitis b surface antigen (anti-hbs) in human serum and plasma (heparinized or edta). Assay results may be used as an aid in the determination of susceptibility to hepatitis b virus (hbv) infection for individuals prior to or following hbv vaccination, or where vaccination status is unknown. Assay results may be used with other hbv serological markers for the laboratory diagnosis of hbv disease associated with hbv infection. A reactive assay result will allow a differential diagnosis in individuals displaying signs and symptoms of hepatitis in whom etiology is unknown. The detection of anti-hbs is indicative of laboratory diagnosis of seroconversion from hepatitis b virus (hbv) infection.

DeviceIMMULITE 2000 XPI ANTI-HBS
Classification NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
Generic NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
ApplicantSiemens Healthcare Diagnostics Products, LTD
Date Received2001-08-31
Decision Date2002-07-22
Notice Date2003-06-24
PMAP010052
SupplementS
Product CodeLOM
Docket Number03M-0287
Advisory CommitteeMicrobiology
Expedited ReviewNo
Combination Product No
Applicant Address Siemens Healthcare Diagnostics Products, LTD glyn Rhonwy llanberis, Caernarfon LL55
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P010052Original Filing
S016 2022-09-15 30-day Notice
S015
S014 2020-08-12 30-day Notice
S013 2019-11-25 30-day Notice
S012 2014-11-28 135 Review Track For 30-day Notice
S011 2011-12-19 135 Review Track For 30-day Notice
S010 2011-08-16 30-day Notice
S009 2011-08-08 30-day Notice
S008 2011-02-18 Real-time Process
S007 2009-11-02 Normal 180 Day Track No User Fee
S006
S005 2008-11-10 Normal 180 Day Track No User Fee
S004 2008-02-25 Normal 180 Day Track
S003 2005-08-17 Special (immediate Track)
S002
S001 2002-11-20 Real-time Process

NIH GUDID Devices

Device IDPMASupp
00630414982182 P010052 001
00630414970998 P010052 001

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.